Skip to main content Accessibility help
×
Home
  • Print publication year: 2020
  • Online publication date: October 2019

Chapter 25 - Screening and Intervention for Fetal Growth Restriction

from Fetal Growth and Well-being

Summary

Fetal growth restriction (FGR) can be defined as the failure of the fetus to meet its genetically predetermined growth potential [1] and is associated with significant fetal and perinatal morbidity and mortality. In addition, there is evidence to suggest a longer-term impact of FGR on childhood neurodevelopmental outcomes [2] and cardiovascular and metabolic diseases that manifest in adulthood [3]. However, predicting FGR is not straightforward and methods for screening and diagnosis are imprecise. In the UK and USA, ultrasound scans in the second half of pregnancy are not performed routinely but targeted at women considered to be at risk for FGR, where high risk is identified by maternal characteristics (including anthropometry and pre-existing disease), the development of complications, or clinical suspicion based on being ‘small for dates’ on physical examination. For practical purposes, FGR may be suspected if biometric measurements are below a given threshold of the distribution in the population, typically <10th, 5th or 3rd centile for gestational age, or if there is a reduction in growth velocity (‘crossing centiles’) from previous scans [4]. The difficulty with using biometry alone is that it does not differentiate between the growth-restricted fetus affected by placental insufficiency, and the healthy, constitutionally small fetus. Therefore, additional measures may be employed to diagnose placental dysfunction, such as Doppler studies of the fetal and uteroplacental circulation, and analysis of maternal serum biomarkers. At present, the only treatment available for FGR is to expedite delivery, but at preterm gestations this can also can cause harm. However, new genomics-based research could help us better understand the etiology of growth restriction and identify more accurate diagnostic biomarkers or potential therapeutic targets. This chapter will focus on current practice in screening for and intervention in FGR and will also consider new developments and the future of the field.

[1]Resnik, R. Intrauterine growth restriction. Obstet Gynecol. 2002; 99: 490–6.
[2]Levine, TA, Grunau, RE, McAuliffe, FM, Pinnamaneni, R, Foran, A, Alderdice, FA. Early childhood neurodevelopment after intrauterine growth restriction: a systematic review. Pediatrics. 2015; 135: 126–41.
[3]Barker, DJP. Adult consequences of fetal growth restriction. Clin Obstet Gynecol. 2006; 49: 270–83.
[4]Gaillard, R, Steegers, EAP, de Jongste, JC, Hofman, A, Jaddoe, VWV. Tracking of fetal growth characteristics during different trimesters and the risks of adverse birth outcomes. Int J Epidemiol. 2014; 43: 1140–53.
[5]Gardosi, J, Kady, SM, McGeown, P, Francis, A, Tonks, A. Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study. BMJ. 2005; 331: 1113.
[6]Partap, U, Sovio, U, Smith, GC. Fetal growth and the risk of spontaneous preterm birth in a prospective cohort study of nulliparous women. Am J Epidemiol. 2016; 184: 110–19.
[7]Lees, C, Marlow, N, Arabin, B, Bilardo, CM, Brezinka, C, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the Trial of Randomized Umbilical and Fetal Flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013; 42: 400–8.
[8]Walker, DM, Marlow, N. Neurocognitive outcome following fetal growth restriction. Arch Dis Child Fetal Neonatal Ed. 2008; 93: F322–5.
[9]Barker, DJP, Godfrey, KM, Gluckman, PD, Harding, JE, Owens, JA, Robinson, JS. Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993; 341: 938–41.
[10]Smith, GC, Wood, AM, White, IR, Pell, JP, Hattie, J. Birth weight and the risk of cardiovascular disease in the maternal grandparents. Am J Epidemiol. 2010; 171: 736–44.
[11]Smith, GCS, Smith, MFS, McNay, MB, Fleming, JEE. First-trimester growth and the risk of low birth weight. N Engl J Med. 1998; 339: 1817–22.
[12]Hadlock, FP, Harrist, RB, Sharman, RS, Deter, RL, Park, SK. Estimation of fetal weight with the use of head, body and femur measurements: A prospective study. Am J Obstet Gynecol. 1985; 151: 333–7.
[13]Royal College of Obstetricians and Gynaecologists. (2014). The Investigation and Management of the Small-for-Gestational-Age Fetus. Green-top Guideline No. 31. www.rcog.org.uk/globalassets/documents/guidelines/gtg_31.pdf
[14]Sovio, U, White, IR, Dacey, A, Pasuparthy, D, Smith, GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015; 386: 2089–97.
[15]Clausson, B, Gardosi, J, Francis, A, Cnattingius, S. Perinatal outcome in SGA births defined by customised versus population-based birthweight standards. BJOG. 2001; 108 : 830–4.
[16]Carberry, AE, Gordon, A, Bond, DM, Hyett, J, Raynes-Greenow, CH, Jeffery, HE. Customised versus population-based growth charts as a screening tool for detecting small for gestational age infants in low-risk pregnant women. Cochrane Database Syst Rev. 2014; 5: CD008549.
[17]Iliodromiti, S, Mackay, DF, Smith, GCS, Pell, JP, Sattar, N, Lawlor, DA, et al. Customised and noncustomised birth weight centiles and prediction of stillbirth and infant mortality and morbidity: a cohort study of 979,912 term singleton pregnancies in Scotland. PLoS Med. 2017; 14: e1002228
[18]Martin, AM, Bindra, R, Curcio, P, Cicero, S, Nicolaides, KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol. 2001; 18: 583–6.
[19]Smith, GC, Yu, CK, Papageorghiou, AT, Cacho, AM, Nicolaides, KH, Fetal Medicine Foundation Second Trimester Screening Group. Maternal uterine Doppler flow velocimetry and the risk of stillbirth. Obstet Gynecol. 2007; 109: 144–51.
[20]Figueras, F, Gratacós, E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014; 36: 8698.
[21]Eixarch, E, Meler, E, Iraola, A, Illa, M, Crispi, F, Hernandez-Andrade, E, et al. Neurodevelopmental outcome in 2-year-old infants who were small-for-gestational age term fetuses with cerebral blood flow redistribution. Ultrasound Obstet Gynecol. 2008; 32: 894–9.
[22]Khalil, A, Morales-Roselló, J, Townsend, R, Morlando, M, Papageorghiou, A, Bhide, A, et al. Value of third-trimester cerebroplacental ratio and uterine artery Doppler indices as predictors of stillbirth and perinatal loss. Ultrasound Obstet Gynecol. 2016; 47: 7480.
[23]Vollgraff Heidweiller-Schreurs, CA, De Boer, MA, Heymans, MW, Schoonmade, LJ, Bossuyt, PMM, Mol, BWJ, et al. Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017; 51: 313–22.
[24]Morris, RK, Selman, TJ, Verma, M, Robson, SC, Kleijnen, J, Khan, KS. Systematic review and meta-analysis of the test accuracy of ductus venosus Doppler to predict compromise of fetal/neonatal wellbeing in high risk pregnancies with placental insufficiency. Eur J Obstet Gynecol Reprod Biol. 2010; 152: 312.
[25]Lees, CC, Marlow, N, vas Wassenaer-Leemhuis, A, Arabin, B, Bilardo, CM, Brezinka, C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015; 385: 2162–72.
[26]Gaccioli, F, Aye, ILMH, Sovio, U, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018; 218: S725–37.
[27]Smith, GC, Stenhouse, EJ, Crossley, JA, Aitken, DA, Cameron, AD, Connor, JM. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia and stillbirth. J Clin Endocrinol Metab. 2002; 87: 1762–7.
[28]Dugoff, L, Hobbins, JC, Malone, FD, Vidaver, J, Sullivan, L, Canick, JA, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005; 106: 260–7.
[29]McCowan, LME, Thompson, JMD, Taylor, RS, Baker, PN, North, RA, Poston, L, et al. Prediction of small for gestational age infants in healthy nulliparous women using clinical and ultrasound risk factors combined with early pregnancy biomarkers. PLoS One. 2017; 12: e0169311.
[30]Smith, GC, Shah, I, Crossley, JA, Aitken, DA, Pell, JP, Nelson, SM, et al. Pregnancy-associated plasma protein A and alpha-fetoprotein and prediction of adverse perinatal outcome. Obstet Gynecol. 2006; 107: 161–6.
[31]Lesmes, C, Gallo, DM, Gonzalez, R, Poon, LC, Nicolaides, KH. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19–24 weeks. Ultrasound Obstet Gynecol. 2015; 46: 341–9.
[32]Karagiannis, G, Akolekar, R, Sarquis, R, Wright, D, Nicolaides, KH. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11–13 weeks. Fetal Diagn Ther. 2011; 29: 148–54.
[33]Valiño, N, Giunta, G, Gallo, DM, Akolekar, R, Nicolaides, KH. Biophysical and biochemical markers at 30–34 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2016; 47: 194202.
[34]Valiño, N, Giunta, G, Gallo, DM, Akolekar, R, Nicolaides, KH. Biophysical and biochemical markers at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol. 2016; 47: 203–9.
[35]Cleaton, MAM, Dent, CL, Howard, M, Corish, JA, Gutteridge, I, Sovio, U, et al. Fetus-derived DLK1 is required for maternal metabolic adaptations to pregnancy and is associated with fetal growth restriction. Nat Genet. 2016; 48: 1473–80.
[36]Hutcheon, JA, Zhang, X, Platt, RW, Cnattingius, S, Kramer, MS. The case against customised birthweight standards. Paediatr Perinat Epidemiol. 2011; 25: 1116.
[37]Gaccioli, F, Sovio, U, Cook, E, Hund, M, Charnock-Jones, DS, Smith, GCS. Screening for fetal growth restriction using ultrasound and the sFLT1:PlGF ratio in a prospective cohort study of nulliparous women. Lancet Child Adolesc Health. 2018; 2: 569–81.
[38]Duley, L, Henderson-Smart, DJ, Meher, S, King, JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007; 2: CD004659.
[39]Groom, KM, McCowan, LM, Mackay, LK, Lee, AC, Said, JM, Kane, SC, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol. 2017; 216: e1296.
[40]Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, MA, Kenny, LC, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018; 2: 93102.
[41]Wyrwoll, CS, Noble, J, Thomson, A, Tesic, D, Miller, MR, Rog-Zielinska, EA, et al. Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess. Proc Natl Acad Sci U S A. 2016; 113: 6265–70.
[42]Brownfoot, FC, Tong, S, Hannan, NJ, Binder, NK, Walker, SP, Cannon, P, et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension. 2015; 66: 687–97.
[43]Brownfoot, FC, Hastie, R, Hannan, NJ, Cannon, P, Tuohey, L, Parry, LJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016; 214: e1356.
[44]Nawaz, FH, Khalid, R, Naru, T, Rizvi, J. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynecol Res. 2008; 34: 832–7.
[45]Onda, K, Tong, S, Beard, S, Binder, N, Muto, M, Senadheera, SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension and rescue endothelial dysfunction. Hypertension. 2017; 69: 457–68.
[46]Miller, SL, Yawno, T, Alers, NO, Castillo-Melendez, M, Supramaniam, VG, van Zyl, N, et al. Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. J Pineal Res. 2014; 56: 283–94.
[47]Chang, EY, Barbosa, E, Paintila, MK, Singh, A, Singh, I. The use of N-acetylcysteine for the prevention of hypertension in the reduced uterine perfusion pressure model for preeclampsia in Sprague-Dawley rats. Am J Obstet Gynecol. 2005; 193: 952–6.
[48]Roes, EM, Raijmakers, MT, de Boo, TM, Zusterzeel, PL, Merkus, HM, Peters, WH, et al. Oral N-acetylcysteine administration does not stabilise the process of established severe preeclampsia. Eur J Obstet Gynecol. 2006; 127: 61–7.
[49]Soothill, PW, Nicolaides, KH, Bilardo, CM, Campbell, S. Relation of fetal hypoxia in growth retardation to mean blood velocity in the fetal aorta. Lancet. 1986; 2: 1118–20.
[50]GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short-term outcomes and Bayesian interpretation. BJOG. 2003; 110: 2732.
[51]Walker, DM, Marlow, N, Upstone, L, Gross, H, Hornbuckle, J, Vail, A, et al. The Growth Restriction Intervention Trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol. 2011; 2014: e1–9.
[52]Morris, RK, Malin, G, Robson, SC, Kleijnen, J, Zamora, J, Khan, KS. Fetal umbilical artery Doppler to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol. 2011; 37: 135–42.
[53]American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no. 134: fetal growth restriction. Obstet Gynecol. 2013; 121: 1122–33.
[54]Whitehead, CL, Walker, SP, Mendis, S, Lappas, M, Tong, S. Quantifying mRNA coding growth genes in the maternal circulation to detect fetal growth restriction. Am J Obstet Gynecol. 2013; 209: e1–9.
[55]Wӧlter, M, Rӧwer, C, Koy, C, Rath, W, Pecks, U, Glocker, MO. Proteoform profiling of peripheral blood serum proteins from pregnant women provides a molecular IUGR signature. J Proteomics. 2016; 149: 4452.
[56]Maitre, L, Fthenou, E, Athersuch, T, Coen, M, Toledano, MB, Holmes, E, et al. Urinary metabolic profiles in early pregnancy are associated with preterm birth and fetal growth restriction in the Rhea mother–child cohort study. BMC Med. 2014; 12: 10.
[57]Pantichob, N, Widdows, KL, Crocker, IP, Johnstone, ED, Please, CP, Sibley, CP, et al. Computational modelling of placental amino acid transfer as an integrated system. Biochim Biophys Acta. 2016; 1858: 1451–61.
[58]Chappell, LC, David, AL. Improving the Pipeline for Developing and Testing Pharmacological Treatments in Pregnancy. PLoS Med. 2016; 13: e1002161.
[59]King, A, Ndifon, C, Lui, S, Widdows, K, Kotamraju, VR, Agemy, L, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016; 2: e1600349.
[60]Cureton, N, Korotkova, I, Baker, B, Greenwood, S, Wareing, M, Kotamraji, VR, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017; 7: 3715–31.
[61]Spencer, R, Ambler, G, Brodszki, J, Diemert, A, Figueras, F, Gratacós, E, et al. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth. 2017; 17: 43.